Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Majorbio Bio-pharm Technology Co., Ltd. (Majorbio) is a leading Chinese life sciences service provider specializing in high-throughput sequencing and multi-omics research. Established in 2009 and headquartered in Shanghai, the company offers a comprehensive suite of services including genomics, transcriptomics, proteomics, and metabolomics to academic, medical, and industrial clients. Majorbio is widely recognized for its proprietary Majorbio Cloud platform, which provides integrated bioinformatics analysis and data visualization tools for complex biological datasets. The company operates state-of-the-art sequencing facilities and supports a wide range of applications, from precision medicine and clinical diagnostics to environmental microbiology and agricultural biotechnology. With a strong focus on innovation, Majorbio has become one of the largest providers of microbial sequencing services in China.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Meiji Biotechnology.